-
Global Molecular Cytogenetics Market Set to Reach USD 1.43 Billion by 2030 | MarketsandMarkets™
11 Dec 2025 15:11 GMT
… , and CROs, molecular cytogenetics is enabling faster treatment decisions … strategic collaborations.
Abbott enhances cytogenetics integration with automated analyzers … Companies in Molecular Cytogenetics and Molecular Cytogenetics Market Size
CONTACT: …
-
Global Molecular Cytogenetics Market Set to Reach USD 1.43 Billion by 2030 | MarketsandMarkets™
11 Dec 2025 14:30 GMT
… companies, and CROs, molecular cytogenetics is enabling faster treatment decisions … strategic collaborations.
Abbott enhances cytogenetics integration with automated analyzers … Companies in Molecular Cytogenetics and Molecular Cytogenetics Market Size
About …
-
<![CDATA[EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma]]>
13 Dec 2025 19:25 GMT
… 29.4% had high-risk cytogenetics among evaluable patients.
Regarding prior …
-
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
13 Dec 2025 01:56 GMT
… analysis and blood sample for cytogenetics.
Hypokalemia, Fluid Retention, and Cardiovascular …
-
Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
11 Dec 2025 13:00 GMT
… integration of OGM into existing cytogenetics and next-generation sequencing (NGS … , its utility compared to traditional cytogenetics and our technologies; our ability …
-
A simple guide for every Indian on how to read your Complete Blood Count (CBC) test report
11 Dec 2025 11:46 GMT
… Head of Molecular Biology and Cytogenetics at Amrita Hospital in Faridabad …
-
<![CDATA[Talquetamab/Pomalidomide Shows Deep Responses in R/R Multiple Myeloma]]>
10 Dec 2025 20:24 GMT
… this cohort had high-risk cytogenetics, and 20.0% had extramedullary …
-
Carfilzomib Improves Upon Bortezomib for Multiple Myeloma
10 Dec 2025 14:13 GMT
… and those with high-risk cytogenetics, Dytfeld and colleagues conducted the … in patients with standard-risk cytogenetics, with median PFS for KRd …
-
<![CDATA[Early Data Show Deep MRD-Negative Responses, CAR T-Cell Persistence With KLN-1010 in R/R Myeloma]]>
10 Dec 2025 01:55 GMT
… chains. Assessment of high-risk cytogenetics showed that patients had the …
-
<![CDATA[BCMA/CD19-Directed CAR T-Cell Therapy Yields 100% ORR in Newly Diagnosed Myeloma]]>
10 Dec 2025 01:55 GMT
… , and 48% had high-risk cytogenetics. Any plasmacytomas were observed in …